WallStSmart

DaVita HealthCare Partners Inc (DVA)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 1459% more annual revenue ($13.64B vs $875.26M). NUTX leads profitability with a 8.1% profit margin vs 5.5%. NUTX trades at a lower P/E of 9.1x. DVA earns a higher WallStSmart Score of 66/100 (B-).

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

NUTX

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 9.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued
NUTXSignificantly Overvalued (-44.5%)

Margin of Safety

-44.5%

Fair Value

$71.26

Current Price

$100.38

$29.12 premium

UndervaluedFair: $71.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

NUTX4 strengths · Avg: 9.5/10
P/E RatioValuation
9.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
58.9%10/10

Every $100 of equity generates 59 in profit

Operating MarginProfitability
97.5%10/10

Strong operational efficiency at 97.5%

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NUTX3 concerns · Avg: 2.3/10
Market CapQuality
$671.69M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-41.1%2/10

Revenue declined 41.1%

EPS GrowthGrowth
-86.2%2/10

Earnings declined 86.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Return on Equity, Operating Margin.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

NUTX carries more volatility with a beta of 2.00 — expect wider price swings.

DVA is growing revenue faster at 9.9% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (66/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?